The aim of this study was to determine the prognostic value of assessing left atrial function during dobutamine stress testing.
C
ardiac stress testing has traditionally concentrated on the imaging and electrical properties of the left ventricle (LV). However, it is increasingly recognized that LV diastolic and systolic performance are intimately connected to left atrial (LA) function and size (1) (2) (3) (4) (5) . For example, impaired relaxation and increased stiffness of the LV, which occur at the earliest stages of ischemia, alter LA loading conditions resulting in changes in atrial function See page 389 and size (6, 7) . Many of these changes occur before any detectable abnormality of LV systolic function (8, 9) . Due to the complexity of LA function and limitations of imaging modalities in quantifying LA changes, potentially important prognostic and diagnostic information regarding the LA during stress testing has not been studied.
Left atrial function has traditionally been described as involving a "reservoir" filling phase during ventricular systole, a "conduit" or "passive" emptying phase during early diastole, and an active "contractile" pumping phase in late diastole (1) . The advent of cardiac magnetic resonance (CMR) imaging with its excellent in-plane spatial resolution and reproducible scan planes allows us to assess these LA properties quantitatively during stress testing. We, therefore, hypothesized that augmentation of LA emptying function measured during staged dobutamine CMR stress testing may provide important prognostic information for predicting cardiac events in a patient cohort with clinical suspicion of coronary artery disease.
M E T H O D S
Study population. We enrolled 122 consecutive patients at Brigham and Women's Hospital, referred for CMR dobutamine stress evaluation of myocardial ischemia due to symptoms suggestive of coronary artery disease (chest pain or shortness of breath). Quantitation of LA emptying function was performed retrospectively. Patients were excluded if they had metallic implants incompatible with CMR, uncontrolled arterial hypertension (baseline systolic blood pressure Ͼ190 mm Hg or diastolic blood pressure Ͼ100 mm Hg), more than mild mitral regurgitation, atrial fibrillation with uncontrolled ventricular response, prior adverse reaction to dobutamine, and acute myocardial infarction (MI) or sustained ventricular tachycardia Ͻ96 h prior to the study. Antianginal medications including oral beta-blockers, calcium channel blockers, and nitrates were not stopped before CMR. All patients provided a detailed history at the time of CMR. A history of high cholesterol was defined by fasting low-density lipoprotein cholesterol Ͼ100 mg/dl or current treatment with cholesterollowering medications. Hypertension was defined by persistent resting systolic blood pressure Ͼ140 mm Hg, diastolic blood pressure Ͼ90 mm Hg, or current treatment with blood pressure-lowering medications. Significant smoking history was defined as Ͼ10 pack-years of cigarette smoking.
Twenty-three healthy volunteers (mean age 32 years, 22% women) with no cardiac history also underwent resting cine imaging, to provide comparative values in the normal population using our new method.
The local institutional review board approved the entire study protocol and clinical follow-up of patients. Informed consent was obtained from all participants immediately before performing CMR. CMR acquisition. Dobutamine CMR was performed with a 1.5-T system (CV/i, General Electric Medical Systems, Milwaukee, Wisconsin) using a 4-to 8-element cardiac phased-array receiver coil. Noninvasive monitoring and gating for image acquisition (9500 monitor, MedRad, Warrendale, Pennsylvania) were performed continuously in all cases. Dobutamine was infused at progressive 5-min stages of 10, 20, 30, and 40 g/kg/min via a separate intravenous line. If a resting regional wall motion abnormality was noted, dobutamine infusion was started at 5 g/kg/min (5/10/ 20/30/40 g/kg/min) in an attempt to capture the increased inotropic response of dysfunctional but viable segments. Intravenous boluses of atropine sulfate (0.25-to 0.4-mg aliquots up to a maximum total dose of 1.5 mg) were used at 30 or 40 g/kg/min stages to augment the heart rate response. Criteria for termination of dobutamine infusion were: 1) achievement of 80% of agepredicted maximum heart rate; 2) development of new systolic wall motion abnormalities; 3) systolic hypotension (Ͻ90 mm Hg); 4) systolic hypertension (Ͼ230 mm Hg); 5) significant chest pain; and 6) complex ventricular arrhythmias. All dobutamine-CMR image acquisitions were performed with electrocardiogram gating and breathholding. Baseline cine steady-state free precession short-axis cines were acquired to cover the entire ventricle in 8 to 14 parallel slices (8-mm thickness and 0-mm spacing, spatial resolution 1.5 ϫ 2 mm, temporal resolution 45 to 50 ms). Cine images were obtained in 3 parallel short-axis (the base, mid, and apex) and 3 radial (3-, 4-, and 2-chamber) views at baseline and at each stress stage. With progressive heart rate increase, the views per segment were lowered (from 16 at rest to the lowest 6) to improve the temporal resolution (to ϳ20 to 25 ms). During dobutamine stress, custom display permitted onthe-fly viewing of LV regional function, either by infusion stage or by slice location. A nurse controlled the dobutamine infusion and monitored the patient's symptoms and electrocardiogram continuously in the scanner room while a physician monitored the acquired images at the imaging console. Vital signs were checked at each dobutamine infusion stage.
Using a previously described inversion-recovery pulse sequence (10) (repetition time: 4.8 ms; echo time: 1.3 ms; in-plane spatial resolution between 1.5 ϫ 1.8 mm and 1.8 ϫ 2.1 mm), late gadolinium enhancement (LGE) images were acquired at slices matching the baseline cine slice locations about 10 to 15 min after intravenous gadoliniumdiethyltriaminepentaacetic acid administration (0.15 to 0.20 mmol/kg; Magnevist, Berlex Pharmaceuticals, Wayne, New Jersey). We optimized the inversion time (200 to 300 ms) to null normal myocardium and adjusted the views per segment according to the patient's heart rate to minimize any image blurring. CMR analysis. Cine function analysis was performed offline with standard validated software (QMASS, Leiden, the Netherlands) (11) . An experienced (level-III CMR-trained) reader manually traced the endocardial contours of the LA in all cine studies. Left atrial areas in the 4-and 2-chamber long-axis views were measured at the end of ventricular systole, just before atrial contraction, and at the end of ventricular diastole. Identification of the correct timing required careful scrolling through the cardiac cycle frame by frame. Maximum atrial volume at end-systole was determined as the frame just before mitral valve opening in early diastole. The timing of the frame before atrial contraction was determined as occurring just before the second upward movement of the mitral annulus away from the apex (the first movement occurred during early diastole). This also corresponded to the frame just before the second opening movement of the mitral valve in diastole. Minimum atrial volume at enddiastole was determined as the frame just before mitral valve closure.
By convention, the inferior LA border was defined as the plane of the mitral annulus and not the tips of the leaflets (12, 13) . Similarly, the atrial appendage, pulmonary veins, and recesses of the mitral valve were excluded by drawing a straight line across these structures to adjacent atrial borders. Atrial length was measured from the midpoint of the mitral annulus plane to the superior margin of the LA in both 4-and 2-chamber views. Left atrial volumes were calculated using the biplane arealength method that has been validated, by CMR, to be accurate and reproducible compared with volumetric analysis: LA volume ϭ (Area 4-chamber ) ϫ (Area 2-chamber ) ϫ 0.85/atrial length (12) (13) (14) . The shorter atrial length from either the 4-or 2-chamber view was used as recommended for this formula.
Left atrial volumes were calculated at the end of ventricular systole (VOL max ), just before atrial contraction (VOL bac ), and at the end of ventricular diastole (VOL min ). Left atrial volume indexes were calculated by dividing each of VOL max , VOL min , and VOL bac by the patient's body surface area calculated by the DuBois formula. From the LA volumes, the following parameters of atrial function were calculated: 1) LA passive emptying fraction (LAPEF) ϭ (VOL max -VOL bac ) ϫ 100%/ VOL max ; 2) LA contractile emptying fraction (LACEF) ϭ (VOL bac -VOL min ) ϫ 100%/ VOL bac ; 3) LA reservoir emptying fraction (LAREF) ϭ (VOL max -VOL min ) ϫ 100%/ VOL max . For each patient, the maximum dobutamine-induced augmentation of these atrial functional parameters was calculated as the maximal increase in absolute percent from rest to stress (⌬LAPEF, ⌬LACEF, and ⌬LAREF, respectively) ( Fig. 1 ). In 30 randomly selected patients, a second level-III CMR trained blinded physician measured the previously mentioned LA dimensions for assessment of interobserver variability.
LV volumes indexed to body surface area and ejection fraction were measured from the short-axis cine images using the Simpson method. LV mass was calculated by subtracting the endocardial volume from the epicardial volume at end-diastole and then multiplying by the tissue density (1.05 g/ml). The short-axis LGE imaging stack of 8 to 14 parallel slices covering the entire LV was used to assess infarct size. The endocardial and epicardial contours on these LGE images were traced manually. Using a semiautomatic detection algorithm, we
applied a signal-intensity threshold of Ն2 SDs above a remote reference myocardial region on the same slice to quantify the total mass extent of any MI (15) .
Wall motion was scored at each dobutamine stage on a 17-segment model using the 4-point index recommended by the American Society of Echocardiography where 1 ϭ normal, 2 ϭ hypokinesia, 3 ϭ akinesia, and 4 ϭ dyskinesia (13) . Dobutamine-induced wall motion abnormality/ ischemia was defined as the presence of segmental wall motion grade increment Ͼ1 during progressive dobutamine stress, except that a progression of segmental akinesia to dyskinesia was considered nonspecific. Apart from the LV apex, a myocardial segment was considered ischemic only if concor- Atrial volumes at end-systole (VOL max ) and before atrial contraction (VOL bac ) are shown at rest and at peak dobutamine stress. Left atrial passive emptying fraction (LAPEF) is defined as (VOL max -VOL bac ) ϫ 100%/VOL max . Left atrial passive emptying function reserve (∆LAPEF) is calculated as the maximum change in LAPEF with dobutamine stress. (A) In this patient there was significant augmentation of left atrial passive function with stress (∆LAPEF ϭ 17%). Such patients had significantly fewer adverse cardiac events during follow-up compared with those with poor augmentation of left passive emptying fraction such as shown in (B). In this patient, there was no augmentation of left atrial passive function with stress. In fact there was a deterioration (∆LAPEF ϭ -3%). dant findings were observed on both the short-axis and matching long-axis views. Follow-up. After CMR, subjects were prospectively followed for a median of 23 months (range 6 to 54 months). The follow-up period was pre-determined to begin after at least 6 months had elapsed from the time of CMR. Patients were contacted once. Clinical follow-up based on a standard questionnaire was obtained from telephone interviews with the patients, relatives, physicians, or from hospital records. Survival status was obtained through a query of the National Social Security Death Index. Major adverse cardiac events (MACE) were defined as death from any cause, acute MI, unstable angina, and development or progression of heart failure. Unstable angina was defined by hospitalization because of chest pain plus either angiographic coronary stenosis of Ͼ70% or significant ischemia on noninvasive stress testing. Development or progression of heart failure was defined as either new hospitalization for heart failure or a need for heart transplantation. When more than 1 of these events occurred, the first event was used in the analysis. Patients who had not experienced a MACE but were referred to undergo coronary revascularization (percutaneous approach or coronary bypass grafting) were censored at the time of the coronary revascularization. Statistical analysis. All continuous variables were expressed as mean Ϯ SD. A p value of Ͻ0.05 was considered statistically significant. Baseline patient characteristics stratified by ⌬LAPEF were compared using the 2-tailed t test and Fisher exact test as appropriate. Interobserver variability was analyzed using the Bland-Altman method (16) . In addition, kappa values were calculated to assess interobserver agreement in categorizing LA function parameters (LAPEF, LACEF, and LAREF) as normal or abnormal. Abnormally low LA function parameters were defined as Ͻ2 SDs from the mean values from our normal population. KaplanMeier analyses for MACE between low and high ⌬LAPEF groups were compared by the log-rank test. We fitted Cox proportional-hazards survival models to estimate the unadjusted hazard ratios (HRs) and the 95% confidence intervals (CIs) of all the variables. For multivariable regression analyses, we further assessed the association of ⌬LAPEF with MACE, adjusted to a set of clinical and LV imaging predictors based on the univariable analysis. We selected the number of variables in each multivariable model to have approximately 1 variable for every 10 events, to reduce overfitting.
Analyses were performed using SAS version 9.1 (SAS Institute, Cary, North Carolina). In the multivariable models, the validity of the proportionalhazards assumption was tested by including a timedependent interaction variable for each of the predictors in each of the models (17) . The global test score in SAS, based on scaled Schoenfeld residuals was used to test for presence of any time-dependent covariates in the models (18) . Using this, we found no evidence of violation of the proportional hazards assumption in any of the final multivariable models.
R E S U L T S Study population. We enrolled 122 consecutive patients of which 14 (11%) were excluded due to inability to complete the dobutamine stress test or poor image quality. Three of these 14 (21%) patients experienced MACE (1 death, 2 congestive heart failure admissions) during follow-up. The remaining 108 patients (67 men, mean age 61 Ϯ 12 years) constituted the study cohort. Table 1 summarizes the clinical characteristics and CMR findings of the study population, stratified by median level of ⌬LAPEF. In some patients, LAPEF deteriorated with stress, resulting in a negative value for ⌬LAPEF. In the current study cohort, mean ⌬LAPEF was 11 Ϯ 14% (median 10.8%, interquartile range 23%, range -16% to 41%). Patients with ⌬LAPEF below the median value had lower baseline LV ejection fractions at rest, larger LV enddiastolic and end-systolic volume indexes, and a trend increase in inducible wall motion deterioration during progressive dobutamine stress. Interobserver variability. Table 2 shows resting LA volumes and LA functional parameters for the group of healthy volunteers and study patients. Bland-Altman analysis of interobserver variability for VOL max , VOL bac , and VOL min showed a bias (Ϯ95% limits of agreement) of 1.5 Ϯ 7.9 ml, 1.0 Ϯ 7.8 ml, and 3.2 Ϯ 7.6 ml, respectively. The BlandAltman plots showed no systematic bias (Fig. 2) . In addition, kappa values were calculated to assess interobserver agreement in detecting abnormally low LA function parameters (LAPEF, LACEF, and LAREF). Abnormally low LA function parameters were defined as Ͻ2 SDs of the means of these parameters measured from the group of 30 randomly selected patients. The interobserver agreement for detection of abnormally low atrial function parameters was good (kappa ϭ 0.75 for LAPEF, kappa ϭ 0.84 for LACEF, and kappa ϭ 0.86 for LAREF).
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Univariable association with MACE. A total of 29 MACE (16 deaths, 3 acute MI, 7 unstable angina, and 3 congestive heart failure episodes requiring hospitalization) occurred during a median follow-up of 23 months. Figure 3 illustrates the Kaplan-Meier survival curves stratified by median ⌬LAPEF. Patients with a ⌬LAPEF Ͻ median experienced a worse event-free survival during the study period than did patients with a ⌬LAPEF Ͼ median (p ϭ 0.004). Table 3 lists the univariable predictors of MACE. As a continuous variable, every 10% decrease in ⌬LAPEF corresponded to an increase in MACE hazards by 56%. Other significant univariable predictors of MACE included patient age and beta-blocker use, as well as the imaging variables of dobutamine-induced wall motion abnormalities, LGE, and resting LA volume at end-diastole (VOL min ). Baseline wall motion score index did not demonstrate any significant association with MACE. Both LV ejection fraction of Ͻ40% and infarct size per 10% change trended toward significance as univariable predictors of MACE Values are mean Ϯ SD or %. ACE ϭ angiotensin-converting enzyme; CABG ϭ coronary artery bypass surgery; CAD ϭ coronary artery disease; EDV ϭ end-diastolic volume; ESV ϭ end-systolic volume; LV ϭ left ventricular; PCI ϭ percutaneous coronary intervention; WMA ϭ wall motion abnormalities. Table 4 illustrates the multivariable analysis of MACE. After adjustment for the effects of beta-blocker use and patient age in years (the 2 strongest univariable clinical predictors of MACE), ⌬LAPEF maintained a strong and independent association with MACE. Every 10% decrease in ⌬LAPEF was associated with a 57% increase in MACE (p ϭ 0.006). Another multivariable model determined the prognostic association of ⌬LAPEF adjusted to the effects of dobutamine-induced wall motion abnormality and presence of LGE (the 2 strongest univariable LV imaging predictors of MACE). Adjusting to presence of myocardial scar by LGE imaging and dobutamine-induced wall motion abnormality, every 10% reduction in ⌬LAPEF was associated with a 57% increase in MACE (p ϭ 0.01). When added to the model that consisted of LGE presence and dobutamine-induced wall motion abnormality, ⌬LAPEF increased the model likelihood ratio chi-square from 8.76 to 16.00 (p Ͻ 0.01). Although increase in wall motion score index (from baseline to peak dobutamine) was a univariable predictor of MACE (Table 3) , it had no significant predictive value after adjustment to ⌬LAPEF (Table 4 ). In addition, ⌬LAPEF maintained a significant association with MACE even after adjustment to both presence of LGE and infarct size (adjusted HR: 1.04/10% change in ⌬LAPEF, 95% CI: 1.01 to 1.08, p ϭ 0.008). Moreover, ⌬LAPEF was associated with MACE independent of the effects of resting LA size. When adjusted to VOL min , ⌬LAPEF still provided incremental association with MACE (adjusted HR: 1.05/10% change in ⌬LAPEF, 95% CI: 1.02 to 1.08, p ϭ 0.003).
Prognostic association of ⌬LAPEF in patients without regional wall motion deterioration during progressive dobutamine stress. Twenty-eight patients (26%) of the cohort demonstrated deterioration of regional LV wall motion that is indicative of myocardial ischemia, whereas the other 80 patients did not. Out of the 80 patients who had no evidence of ischemia, 16 experienced MACE in the follow-up period (including 7 deaths, 2 acute MIs, 6 unstable angina hospitalizations, and 1 heart failure hospitalization). In these patients, ⌬LAPEF Ͻ median is strongly associated with MACE despite a lack of evidence for myocardial ischemia by wall motion abnormality. In this subset of patients, every 10% reduction of ⌬LAPEF was associated with a 56% increase in MACE hazards (HR: 1.56, 95% CI: 1.06 to 2.30, chi-square likelihood ratio: 5.03).
D I S C U S S I O N
To our knowledge, this is the first study to quantitatively evaluate LA emptying function Bland-Altman analysis of inter-observer variability for (A) VOL max , (B) VOL bac , and (C) VOL min . VOL min ϭ left atrial volume at enddiastole; other abbreviations as in Figure 1 .
during cardiac stress testing. Our data indicate that reduced augmentation of passive LA emptying fraction (⌬LAPEF) is a predictor of cardiac events. Every 10% decrease in ⌬LAPEF is associated with a 57% increase in MACE, after adjusting for presence of inducible ischemia and myocardial scar. We have provided preliminary data from a pilot clinical cohort with relatively few adverse events and consequently limited multivariable adjustments were possible. Nevertheless, these findings are suggestive of a close inter-relationship between stress-induced LA and diastolic dysfunction with adverse outcomes. LA function and ventricular performance. The close coupling between LV and LA function highlights the somewhat artificial distinction made between these 2 properties (1-5). During LV systole, the downward movement of the mitral annulus stretches the atria so that atrial and ventricular volumes reciprocate. This is also the case during early diastolic LA emptying, when ventricular relaxation and elastic recoil move the mitral annulus upward, significantly contributing to LV filling. This has led some to suggest that these LA functional properties should really be thought of as LV properties (19) . Atrial function and MACE. Kizer et al. (20) showed that LA pumping function at rest can predict cardiac events in a population-based cohort. We have shown that an inability to augment LA passive emptying fraction with stress is a predictor of poor outcome. Presumably, these patients are unable to increase early diastolic filling by improving active relaxation or ventricular suction. Thus, augmentation of LA passive function may be a measure of early diastolic functional reserve. We have shown that ischemia as detected by new or worsening LV wall motion abnormalities with stress was not an independent predictor of MACE when adjusted for the effects of LA passive functional reserve. This maybe because diastolic abnormalities responsible for failure of LA passive function augmentation precede obvious systolic wall motion deterioration as described in the concept of the ischemic cascade (8, 9, 21) . LA function during ischemia. A significant body of animal and human experimental data has shown that during an ischemic insult, changes in diastolic LV function occur before any changes in systolic wall motion (6 -9,21) . Thus, relying on detection of systolic wall motion abnormalities alone may result in missing some patients with early ischemia. Similarly, changes in LA function during angioplasty have been shown to precede changes in LV systolic function (7) .
There are several possible mechanisms by which ischemia leads to abnormalities of ventricular filling early in diastole and thus to a diminution of LA passive functional reserve (8, 22) : 1) myocardial relaxation is an exquisitely energy-dependent process and highly sensitive to the effects of ischemia, because adenosine triphosphate hydrolysis is needed to release tightly bound actin-myosin bonds and for calcium reuptake into the sarcoplasmic reticulum; and 2) subendocardial longitudinal fibers are particularly sensitive to ischemia. This leads to uncoordinated or asynchronous relaxation between circumferential and longitudinal fibers in ischemic areas, as well as a reduction in longitudinal contractile function that may not be initially detectable but which could lead to diminished ventricular suction. It should be noted that classical markers of LV diastolic function were not measured in the current study. It would be of interest to know if LA functional parameters (such as ⌬LAPEF) are more sensitive to LV ischemia than classical diastolic markers.
Relative prognostic importance of atrial reservoir, passive, and pump functions. Our study did not show a significant prognostic effect of changes in atrial reservoir or contractile function on future cardiac events. It has been shown that transient ischemia The boldfaced values are statistically significant. HR ϭ hazard ratio; LR ϭ likelihood ratio; MACE ϭ major adverse cardiac events; ∆LACEF ϭ maximum augmentation in left atrial contractile emptying fraction; ∆LAPEF ϭ maximum augmentation in left atrial passive emptying fraction; ∆LAREF ϭ maximum augmentation in left atrial reservoir emptying fraction; other abbreviations as in Tables 1 and 2 . tends to increase atrial contractile function (the atrial booster pump), mildly decrease atrial reservoir function, and profoundly decrease atrial passive function (6) . This suggests that our finding of prognostic significance only with atrial passive function may be because it is the most sensitive marker of ischemia due to the particular energy dependence of early myocardial relaxation as opposed to other aspects of diastolic function. Study limitations. Given the small study size, the current multivariable models were limited to a few selected clinical and LV imaging variables. Thus, we were unable to estimate the association of ⌬LAPEF with MACE when simultaneously adjusted to all possible predictors. Also given the small study size, the possibility of selection bias must be kept in mind, particularly given the relatively high event rates that were observed in those with no stress-induced wall motion abnormalities. At the time of this study, stress CMR was not the first line stress test at our institution. It is therefore likely that there was selection bias present with predominantly more complex and sicker patients referred for this examination. The risk associated with a negative test is highly dependent on the underlying population risk. For example, others have found MACE rates in high risk patients with LV dysfunction and a negative dobutamine stress CMR of around 30% at 24 months (23). Thus although our event rates are high in the negative stress test group, this is likely a reflection of the sick population studied. Finally, although the LA volumes measured in our normal subjects are high compared with those reported in the echocardiographic literature, they are similar to recently reported CMR reference ranges (40.0 Ϯ 6.7 ml/m 2 ) (24,25).
C O N C L U S I O N S Augmentation of LA passive emptying fraction during dobutamine stress, quantified by CMR, is a predictor of cardiovascular prognosis, independent of major clinical or LV imaging predictors. Our findings are consistent with a close relationship between LA passive emptying function and LV diastolic dysfunction. However, the mechanisms linking stress-induced changes in LA function with adverse outcomes require further study. 
